Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
Abstract Background Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor (NNRTI) available in France since 2006, is indicated for antiretroviral-experienced HIV-infected adults, in combination with a ritonavir-boosted protease inhibitor (PI). To assess its clinical impact in routine ca...
שמור ב:
| Principais autores: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMC
2018-07-01
|
| סדרה: | BMC Infectious Diseases |
| נושאים: | |
| גישה מקוונת: | http://link.springer.com/article/10.1186/s12879-018-3231-5 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
